Chiara Borsari

Title: Chiara Borsari: Inventor of Covalent PI3Kα Inhibitors.

Introduction

Chiara Borsari is an inventor associated with the University of Basel in Basel, Switzerland. Her patent work concerns triazine compounds designed as reversible and irreversible covalent inhibitors of phosphoinositide 3-kinase alpha (PI3Kα), an enzyme implicated in cancer and metabolism.

Latest Patents

Borsari is named on one patent: “Triazine Derivative as Reversible and Irreversible Covalent Inhibitors of PI3K.” The invention describes triazine compounds with reactive chemical groups, or “warheads,” and linkers designed to reach a solvent-exposed cysteine more than 10 angstroms from the core reversible inhibitor. It explores different exit vectors to adjust the compounds’ reactivity and their efficiency in forming covalent bonds.

The disclosed compounds are optimized covalent modifiers of PI3Kα. The patent presents them as potential therapeutic agents and chemical probes for studying PI3K isoforms, with possible applications in research on PI3Kα-driven cancers and malformations.

Career Highlights

The available information identifies Borsari’s patent contribution and her association with the University of Basel. Her work reflects an approach to inhibitor design that combines reversible binding with covalent modification.

Collaborations

Matthias Wymann is identified as a coworker associated with Borsari’s work.

Conclusion

Chiara Borsari’s patent contribution focuses on triazine-based covalent inhibitors that may support research into PI3K biology and the development of treatments for PI3Kα-related conditions.